What if we made stratified medicine work for patients?

[1]  R. Hubbard,et al.  Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. , 2015, The Lancet. Respiratory medicine.

[2]  K. Chamberlain,et al.  Home as a hybrid centre of medication practice. , 2020, Sociology of health & illness.

[3]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[4]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[5]  J. Bell.  Stratified medicines: towards better treatment for disease , 2014, The Lancet.

[6]  J. Beck,et al.  Cancer Patients’ Trade-offs Among Efficacy, Toxicity, and Out-of-Pocket Cost in the Curative and Noncurative Setting , 2013, Medical care.

[7]  Brent S. Pedersen,et al.  Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis , 2013, Nature Genetics.

[8]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[9]  Carl May,et al.  We need minimally disruptive medicine , 2009, BMJ : British Medical Journal.

[10]  L. Mccoy,et al.  Time, self and the medication day: a closer look at the everyday work of 'adherence'. , 2009, Sociology of health & illness.

[11]  C. Pope,et al.  Qualitative Research in Health Care: Third Edition , 2007 .

[12]  Catherine Pope,et al.  Resisting medicines: a synthesis of qualitative studies of medicine taking. , 2005, Social science & medicine.